Ophthalmopathology in Sharpe’s syndrome
https://doi.org/10.21516/2072-0076-2025-18-3-147-151
Abstract
This review is devoted to Sharp syndrome, which is an autoimmune disease of connective tissue with mixed signs of several pathologies at once (systemic scleroderma, systemic lupus erythematosus, rheumatoid arthritis, dermatoor poliomyositis). This causes clinical diversity of the clinical picture, so the diagnosis of patients with Sharp syndrome, especially in the early stages of the disease, is a difficult task for clinical practice. In approximately more than half of the cases, over time, transformation into one or another specific nosological form is possible. Eye damage is diagnosed in about a third of patients and is usually an indicator of disease activity. In this case, ophthalmologic manifestations differ and range from relatively “harmless” dry keratoconjunctivitis (which is most often recorded in all diseases included in this syndrome) and episcleritis to severe scleritis and uveitis (from iridocyclitis to panuveitis), as well as retinovasculitis, leading to severe visual impairment. Treatment of Sharp syndrome is reduced to the use of non-steroidal anti-inflammatory drugs and corticosteroids, including pulse therapy, and then basic antirheumatic drugs (immunosuppressants, etc.).
About the Authors
O. I. Orenburkina
Russian Center for Eye and Plastic Surgery, Bashkir State Medical University;
Peoples’ Friendship University of Russia named after Patrice Lumumba
Russian Federation
Russian Federation
Olga I. Orenburkina — Dr. of Med. Sci., director, Russian Center for Eye and Plastic Surgery, Bashkir State Medical University, associate professor of chair of eye diseases, Peoples’ Friendship University of Russia named after Patrice Lumumba
67, Bldg. 1, Richard Sorge St., Ufa, 450075,
6, Miklukho-Maklaya St., Moscow, 117198
A. E. Babushkin
Ufa Eye Research Institute, Bashkir State Medical University
Russian Federation
Russian Federation
Aleksandr E. Babushkin — Dr. of Med. Sci., head of the department of scientific research and development arrangement
90, Pushkin St., Ufa, 450008
A. M. Frolov
Peoples’ Friendship University of Russia named after Patrice Lumumba
Russian Federation
Russian Federation
Alexandr M. Frolov — Cand. of Med. Sci., associate professor, associate professor of chair of eye diseases
6, Miklukho-Maklaya St., Moscow, 117198
D. I. Koshelev
Russian Center for Eye and Plastic Surgery, Bashkir State Medical University
Russian Federation
Russian Federation
Dmitry I. Koshelev — Cand. of Biol. Sci., associate professor, head of the laboratory of neurophysiology of vision
67, Bldg. 1, Richard Sorge St., Ufa, 450075
References
1. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med. 1972; 52 (2): 148–59. doi: 10.1016/0002-9343(72)90064-2
2. Nasonov E.L., Nasonova V.A. Rheumatology: national guidelines. Moscow: GEOTAR-Media; 2010 (In Russ.).
3. Alekperov RT. Mixed connective tissue disease, un differentiated connective tissue disease and overlap syndromes. Almanac of clinical medicine. 2019; 47 (5): 435–44 (In Russ.). doi: 10.18786/2072-0505-2019-47-022
4. John KJ, Sadiq M, George T, et al. Clinical and immunological profile of mixed connective tissue disease and a comparison of four diagnostic criteria. Int J Rheumatol. 2020; 2020: 9692030. doi: 10.1155/2020/9692030
5. Tarvin SE, O’Neil KM. Systemic lupus erythematosus, Sjogren syndrome, and mixed connective tissue disease in children and adolescents. Pediatr Clin North Am. 2018 Aug; 65 (4): 711–37. doi: 10.1016/j.pcl.2018.04.001
6. Shaporeva K.R., Lapshina S.A., Sukhorukova E.V., et al. Sharp’s syndrome: from basic anti-inflammatory therapy to genetically engineered biological drugs. Practical medicine. 2023; 21 (3): 146–9 (In Russ.). https://pmarchive.ru/sindrom-sharpa-ot-bazisnoj-protivovospalitelnoj-terapii-k-gennoinzhenernym-biologicheskim-preparatam/
7. Flam ST, Gunnarsson R, Garen T, et al. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology (Oxford). 2015 Mar; 54 (3): 528–35. doi: 10.1093/rheumatology/keu310
8. Vardanyan A.G., Soboleva V.N., Volov N.A., et al. Sharp syndrome: diagnostic difficulties. Therapy. 2018; 7–8: 133–8 (In Russ.). doi: 10.18565/therapy.2018.7-8.133-138
9. Gunnarsson R, Hetlevik SO, Lilleby V, et al. Mixed connective tissue disease. Best Pract Res Clin Rheumatol. 2016 Feb; 30 (1): 95–111. doi: 10.1016/j.berh.2016.03.002
10. Makarova T.P., Vakhitov Kh.M., Sabirova D.R., et al. Evolution of mixed connective tissue disease in 7 years old child: Clinical case. Current Pediatrics. 2020; 19 (3): 214–9 (In Russ.). doi: 10.15690/vsp.v19i3.2117
11. Pepmueller PH. Undifferentiated connective tissue disease, mixed connective tissue disease, and overlap syndromes in rheumatology. Mo Med. 2016 Mar-Ap; 113 (2): 136–40. PMID: 27311225.
12. Sitaula R, Shah DN, Singh D. The spectrum of ocular involvement in systemic lupus erythematosus in a tertiary eye care center in Nepal. Ocul Immunol Inflamm. 2011; 19: 422–5. doi: 10.3109/09273948.2011.610023
13. El-Shereef RR, Mohamed AS, Hamdy L. Ocular manifestation of systemic lupus erythematosus. Rheumatol Int. 2013; 33: 1637–42. doi: 10.1007/s00296-011-2296-x
14. Dias-Santos A, Tavares Ferreira J, et al. Ocular involvement in systemic lupus erythematosus patients: a paradigm shift based on the experience of a tertiary referral center. Lupus. 2020; 29: 283–9. doi: 10.1177/0961203320903080
15. Turk MA, Hayworth JL, Nevskaya T, Pope JE. Ocular manifestations in rheumatoid arthritis, connective tissue disease, and vasculitis: A systematic review and metaanalysis. J Rheumatol. 2021; 48: 25–34. doi: 10.3899/jrheum.190768
16. Babu K, Nanda S, Hegde P, et al. Posterior segment involvement in systemic lupus erythematosus — a series from South India. Indian J Ophthalmol. 2023; 71: 1986–93. doi: 10.4103/ijo.IJO_1705_22
17. Rudneva L.F., Ponomareva E.Yu. Ophthalmological manifestations in rheumatoid arthritis (literature review). Medical Science and Education of the Urals. 2018; 3 (95): 168–70 (In Russ.).
18. Zlatanović G, Veselinović D, Cekić S, et al. Ocular manifestation of rheumatoid arthritis-different forms and frequency. Bosn J Basic Med Sci. 2010 Nov; 10 (4): 323–7. doi: 10.17305/bjbms.2010.2680
19. Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012; 2012: 290898. doi: 10.1155/2012/290898
20. Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016; 100: 135–41. doi: 10.1136/bjophthalmol-2015-306629
21. Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 2018; 18: 135–49. doi: 10.1007/s10238-017-0479-9
22. Meng L, Wang Y, Yang Z, et al. Ocular fundus changes and association with systemic conditions in systemic lupus erythematosus. Front Immunol. 2024; 15: 1395609. doi: 10.3389/fimmu.2024.1395609
23. Ungprasert P, Crowson CS, Chowdhary VR, et al. Epidemiology of mixed connective tissue disease, 1985–2014: A population-based study. Arthritis Care Res (Hoboken). 2016; 68 (12): 1843–8.
24. Belskaya K.I., Obrubov A.S., Shirshova E.V., Burdenko I.G., Panina E.N. A case of manifestation of systemic lupus erythematosus in the form of occlusive retinovasculitis. Modern technologies in ophthalmology. 2017; 4: 29–32 (In Russ.).
25. Razumova I.Yu., Godzenko A.A. New possibilities in therapy of ocular inflammation in rheumatic diseases. Vestnik oftal’mologii. 2022; 138 (6): 108–14 (In Russ.). doi: 10.17116/oftalma2022138061108
26. Artifoni M, Rothschild PR, Brézin A, Guillevin L, Puéchal X. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol. 2014 Feb; 10 (2): 108–16. doi: 10.1038/nrrheum.2013.185
27. Promelle V, Goeb V, Gueudry J. Rheumatoid arthritis associated episcleritis and scleritis: An update on treatment perspectives. J Clin Med. 2021 May 14; 10 (10): 2118. doi: 10.3390/jcm10102118
28. Corbitt K, Nowatzky J. Inflammatory eye disease for rheumatologists. Curr Opin Rheumatol. 2023; 35 (3): 201–12. doi:10.1097/BOR.0000000000000933
29. Trukhan D.I., Lebedev O.I. Changes in the organ of vision in somatic diseases. Therapeutic archive. 2015; 8: 132–6 (In Russ.). doi: 10.17116/terarkh2015878132-136
30. Jawahar N, Walker JK, Murray PI, Gordon C, Reynolds JA. Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus: A systematic review. Lupus. 2021; 30: 2191–203. doi: 10.1177/09612033211050337
31. Spitsina S.S., Shilova L.N., Mozgovaya E.E., Bedina S.A., Trofimenko A.S. Ophthalmologic manifestations of systemic lupus erythematosus: the effect of autoimmune inflammation. Medical alphabet. 2024; 29: 50–5 (In Russ.). doi: 10.33667/2078-5631-2024-29-50-55
32. Ho T-Y, Chung Y-M, Lee A-F, Tsai C-Y. Severe vaso-occlusive retinopathy as the primary manifestation in a patient with systemic lupus erythematosus. J Chin Med Assoc. 2008; 71 (7): 377–80.
33. Luboń W, Luboń M, Kotyla P, Mrukwa-Kominek E. Understanding ocular findings and manifestations of systemic lupus erythematosus: Update review of the literature. Int J Mol Sci. 2022; 23. doi: 10.3390/ijms232012264
34. Zannin ME, Martini G, Athreya BH, еt al. Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol. 2007 Oct; 91 (10): 1311–4. doi: 10.1136/bjo.2007.116038
35. Babushkin A.E., Karabanova I.V., Akhmaletdinova V.M. A case of dry keratoconjunctivitis in a patient with Sharp syndrome. Collection of scientific papers of the int. scientific and practical. conf. on ophthalmology “East — West”. Ufa, 2010: 61–3 (In Russ.).
36. Burkhanov Yu.K., Malkhanov V.B., Absalikova D.K., Nikitin N.A. Sharp’s syndrome: clinical and diagnostic measures and treatment (case report). East — West. 2011: 492 (In Russ.).
37. Lebedev O.I., Surov A.V., Matnenko T.Yu., Salikhov M.M. Immunotherapy of uveitis associated with systemic diseases. RMJ. Clinical ophthalmology. 2013; 2: 69–71 (In Russ.).
Review
For citations:
Orenburkina O.I., Babushkin A.E., Frolov A.M., Koshelev D.I. Ophthalmopathology in Sharpe’s syndrome. Russian Ophthalmological Journal. 2025;18(3):147-151. (In Russ.) https://doi.org/10.21516/2072-0076-2025-18-3-147-151
Views:
8
Email this article 